US 12,304,908 B2
Azabenzimidazoles and their use as AMPA receptor modulators
Michael K. Ameriks, San Diego, CA (US); Cynthia G. B. Berry, San Diego, CA (US); Gang Chen, San Diego, CA (US); Fabrice Loic Jourdan, Olias del Rey (ES); Terry Patrick Lebold, San Diego, CA (US); David Wei Lin, San Diego, CA (US); Miguel Angel Pena Piñon, Olias del Rey (ES); Suchitra Ravula, San Diego, CA (US); Bradley M. Savall, San Diego, CA (US); Devin M. Swanson, Carlsbad, CA (US); Dongpei Wu, San Diego, CA (US); and Wei Zhang, San Diego, CA (US)
Assigned to Rapport Therapeutics, Inc., Boston, MA (US)
Filed by Rapport Therapeutics, Inc., Boston, MA (US)
Filed on May 19, 2021, as Appl. No. 17/324,520.
Application 17/324,520 is a continuation of application No. 15/569,299, granted, now 11,312,712, previously published as PCT/US2016/029801, filed on Apr. 28, 2016.
Claims priority of provisional application 62/154,313, filed on Apr. 29, 2015.
Prior Publication US 2021/0284641 A1, Sep. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61P 25/00 (2006.01); C07D 471/14 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 25/00 (2018.01); C07D 471/14 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05)] 2 Claims
 
1. A compound, wherein the compound is 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)imidazo[4,5-b]pyridine, or a pharmaceutically acceptable salt thereof.